Founded by
'Metsera was purpose-built over the last two years to get ahead of the innovation curve in one of the largest and fastest growing markets in the history of biopharma,' said
Metsera has raised
'We are in the early days of an incredibly exciting new era of innovation in weight loss and obesity associated diseases,' said
Advancing Broad Portfolio of Next-generation Weight Loss Medicines
Metsera's portfolio of next-generation injectable and oral development programs is sourced from the company's proprietary library of over 20,000 gut hormone peptides and peptide/antibody conjugates. Development programs include parallel strategies and are focused on multiple next-generation targets and combinations.
These include: GLP-1 portfolio: led by an injectable, fully-biased GLP-1 receptor agonist in Phase 1 clinical trials with a potential class-leading duration of effect
A dual amylin/calcitonin receptor agonist (DACRA) engineered for class-leading duration of effect which is being combined with the GLP-1 receptor agonist
A unimolecular GGG (GLP-1, GIP, Glucagon) engineered for class-leading duration of effect and combination with DACRA
An oral peptide delivery platform, including two IND-ready candidates with potential best-inclass bioavailability and multiple first-in-class oral follow-on candidates
A range of other early-stage programs and delivery modalities
'Metsera's portfolio is designed to unlock new treatment strategies through scalable, sustainable and personalized interventions for weight loss, weight maintenance and disease prevention,' said Sir
About Metsera
Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Founded in 2022 by
Contact:
Email: dan@1abmedia.com
(C) 2024 Electronic News Publishing, source